Stockscreener 앱 받기
1.84
3.16%
-0.06
시간 외 거래:
1.89
0.05
+2.72%
전일 마감가:
$1.90
열려 있는:
$1.92
하루 거래량:
93,530
Relative Volume:
0.38
시가총액:
$136.79M
수익:
-
순이익/손실:
$-19.57M
주가수익비율:
-0.5879
EPS:
-3.13
순현금흐름:
$-17.24M
1주 성능:
-0.54%
1개월 성능:
+8.24%
6개월 성능:
-32.35%
1년 성능:
+26.03%
1일 변동 폭
$1.83
$1.92
1주일 범위
$1.76
$1.97
52주 변동 폭
$1.12
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
명칭
Inhibikase Therapeutics Inc
전화
678-392-3419
주소
3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA
IKT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.84 | 137.53M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-12 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc 주식(IKT)의 최신 뉴스
What drives Inhibikase Therapeutics Inc. stock priceTremendous return on equity - PrintWeekIndia
Inhibikase Therapeutics Inc. Stock Analysis and ForecastDynamic profit expansion - Autocar Professional
Is Inhibikase Therapeutics Inc. a good long term investmentSkyrocketing investment returns - Autocar Professional
What analysts say about Inhibikase Therapeutics Inc. stockRecord-breaking gains - jammulinksnews.com
What risks could impact Inhibikase Therapeutics Inc. stock performance2x Return Forecast - Newser
Why Inhibikase Therapeutics Inc. stock attracts strong analyst attentionSmart High Yield Swing Trades - beatles.ru
How Inhibikase Therapeutics Inc. stock performs during market volatilityFree Step-by-Step Investment Guide - beatles.ru
What makes Inhibikase Therapeutics Inc. stock price move sharplyFree Stock Market Forums - Newser
Inhibikase Therapeutics Approves Key Proposals at Annual Meeting - The Globe and Mail
Inhibikase Therapeutics shareholders elect directors and approve equity plan changes - Investing.com India
Inhibikase Therapeutics Soars 6.79% on Russell 2000 Index Addition - AInvest
Inhibikase Therapeutics, Inc.(NasdaqCM: IKT) added to Russell 2000 Index - MarketScreener
IKT SEC FilingsInhibikase Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Ludwig Enterprises appoints Garth Lees-Rolfe as independent director By Investing.com - Investing.com UK
Squarepoint Ops LLC Acquires Shares of 28,411 Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Millennium Management LLC Invests $462,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Northern Trust Corp Invests $208,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Inhibikase Therapeutics Insider Buyers Pleased With US$788k Return On Investment - simplywall.st
Inhibikase Therapeutics Reports Q1 2025 Financial Results - TipRanks
13,129 Shares in Inhibikase Therapeutics, Inc. (NYSE:IKT) Purchased by Stifel Financial Corp - Defense World
Inhibikase Therapeutics: Strategic Realignment and Financial Strength Justify Buy Rating - TipRanks
Inhibikase Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Inhibikase Therapeutics, Inc. SEC 10-Q Report - TradingView
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity - The Manila Times
Inhibikase Reports $93M War Chest, Accelerates Revolutionary PAH Treatment Development - Stock Titan
Barclays PLC Purchases New Holdings in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Former Inhibikase leader launches new biotech for midstage Parkinson's asset - Fierce Biotech
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT) - PR Newswire
Inhibikase Therapeutics: A Hold With Uncertain Prospects In PAH - Seeking Alpha
Geode Capital Management LLC Purchases 272,813 Shares of Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
IKTInhibikase Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
In wake of Anthos buyout, CFO McIntyre joins Inhibikase - BioCentury
Inhibikase Therapeutics Advances PAH Treatment with New Leadership - TipRanks
Inhibikase Therapeutics appoints new CFO By Investing.com - Investing.com South Africa
Inhibikase Therapeutics Names David McIntyre as CFO - marketscreener.com
Inhibikase Therapeutics Announces Appointment Of David Mcintyre As CFO - marketscreener.com
Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise - MSN
Inhibikase Therapeutics Inc (IKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.59%
0.34%
자본화:
|
볼륨(24시간):